In BC, TK activation as a driving oncogenic event has been clearly described with ERBB2 amplification, and prognostic kinase-based GESs have been reported in basal BCs [9], luminal BCs [20], and ER-negative BCs including ERBB2-positive tumors and basal tumors [21]. Here, ERBB2 is linked to breast cancer.